Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

NUWE

N

Nuwellis, Inc. (NUWE)

NCM – Real Time Price. Currency in USD

1.05

-0.07 (-6.24%)

At close: Mar 27, 2026, 4:00 PM EDT

1.03

-0.02 (-1.90%)

After-hours: Mar 27, 2026, 7:19 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Nuwellis Completes Acquisition of Rendiatech

Nuwellis Completes Acquisition of Rendiatech

MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd.

Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript

Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript

Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy.

Nuwellis Appoints David A. McDonald and Martin J.

Nuwellis Appoints David A. McDonald and Martin J.

MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J.

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.

Nuwellis Appoints Carisa Schultz as Chief Financial Officer

Nuwellis Appoints Carisa Schultz as Chief Financial Officer

Schultz brings public company healthcare finance and medical technology experience to support Nuwellis' next phase of growth Schultz brings public company healthcare finance and medical technology experience to support Nuwellis' next phase of growth

Videos

No Data

There is no data to display

Press releases

Nuwellis Completes Acquisition of Rendiatech

Nuwellis Completes Acquisition of Rendiatech

MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd.

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy.

Nuwellis Appoints David A. McDonald and Martin J.

Nuwellis Appoints David A. McDonald and Martin J.

MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J.